Results 31 to 40 of about 2,895 (208)

A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis

Saudi Journal of Kidney Diseases and Transplantation, 2014
In the present study, a comparative evaluation of the effects of calcium acetate, calcium carbonate, sevelamer hydrochloride and lanthanum carbonate was carried out in 120 patients with end stage kidney disease (ESKD) undergoing hemodialysis. Biochemical
Viken A Prajapati, Varsha J Galani, Pankaj R Shah   +2 more
doaj   +1 more source

Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia [PDF]

, 2011
Because of an elevated serum phosphate level, patients who suffer from chronic kidney failure frequently tend to have cardiovascular calcification and are therefore exposed to a higher probability of a fatal event.
Mittendorf, Thomas, Plagemann, Thomas, Prenzler, Anne   +2 more
core   +2 more sources

Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial

Kidney International Reports, 2020
Introduction: Calciprotein particles (CPPs) are potentially modifiable mediators of phosphate toxicity in patients with kidney disease. We compared the effects of calcium carbonate (CC) and the non–calcium-based phosphate binder sevelamer on CPP levels ...
Edward R. Smith, Fei Fei M. Pan, Tim D. Hewitson, Nigel D. Toussaint, Stephen G. Holt   +4 more
doaj   +1 more source

Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial

BMC Nephrology, 2012
Background Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone that is secreted from bone and serum level increases as renal function declines.
Bleskestad Inger H, Bergrem Harald, Hartmann Anders, Godang Kristin, Gøransson Lasse G   +4 more
doaj   +1 more source

Phosphorus binders: preferences of patients on hemodialysis and its impact on treatment compliance and phosphorus control [PDF]

, 2010
Introducción: En la actualidad disponemos de un amplio abanico de captores del fósforo (CF), pero sabemos poco acerca de las preferencias de los pacientes y de su repercusión sobre el cumplimiento del tratamiento y el control de los niveles de fósforo ...
Arenas Jiménez, María Dolores, Gil González, María Teresa, Malek, Tamara, Moledous, Analía, Reig-Ferrer, Abilio, Álvarez Ude, Fernando   +5 more
core   +2 more sources

Use of phosphate binders in end-stage renal disease: An experience from a secondary care hospital in United Arab Emirates

Journal of Pharmacy and Bioallied Sciences, 2019
Objective: Hyperphosphatemia in end-stage renal disease (ESRD) is associated with many serious patient-level consequences including cardiovascular events and mortality.
Syed Arman Rabbani, Sathvik B Sridhar, Padma G M Rao, Martin T Kurian, Basset E Essawy   +4 more
doaj   +1 more source

Phosphorous metabolism and manipulation in chronic kidney disease. [PDF]

Nephrology (Carlton)
Summary at glance Chronic kidney disease‐mineral bone disorder (CKD‐MBD) is commonly seen in individuals with impaired renal function. Phosphate balance is crucial, involving key factors like vitamin D, parathyroid hormone (PTH), calciprotein particles (CPPs) and fibroblast growth factor‐23 (FGF‐23).
Marando M, Tamburello A, Salera D, Di Lullo L, Bellasi A.   +4 more
europepmc   +2 more sources

Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease [PDF]

, 2016
Secondary hyperparathyroidism (SHPT) is a common complication of CKD and is part of the chronic kidney disease-mineral bone disorder (CKD-MBD). SHPT is associated with increased risk of fracture and mortality, thus SHPT control is recommended as kidney ...
Khwaja, A., Salam, S.N., Wilkie, M.E.
core   +1 more source

Lanthanum associated abnormal liver function tests in two patients on dialysis: a case report [PDF]

, 2009
Lanthanum (La) is a phosphate binder used in patients on dialysis in the UK. As it has only recently been in use, there are no long-term data about safety of this rare metal in human subjects with renal failure on renal replacement therapy.
Daryanani Indiver, Sathyamurthy Sangita, Mooney Joanne, Yates Lucy, Main Norman, Namagondlu Girish, Crowe Alex, Ledson Tom, Banerjee Anindya   +8 more
core   +2 more sources

Chronic kidney disease mineral and bone disorder in children [PDF]

, 2007
Childhood and adolescence are crucial times for the development of a healthy skeletal and cardiovascular system. Disordered mineral and bone metabolism accompany chronic kidney disease (CKD) and present significant obstacles to optimal bone strength ...
Katherine Wesseling, Sevcan Bakkaloglu, Isidro Salusky   +2 more
core   +1 more source